Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

GLP-1RA

December 09, 2019

Sanofi Discontinues Efpeg Development

Here is a brief preview of this blast: Ahead of Sanofi's Capital Markets Day on December 10, 2019, the company issued a press release outlining its new commercial strategy and direction. As part of the new strategy, Sanofi disclosed that it is no longer pursuing commercialization of its QW GLP-1RA, efpeglenatide (in partnership with Hanmi). Tomorrow, FENIX will be providing full coverage of Sanofi's Capital Markets Day.